Abstract
In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.
Original language | English |
---|---|
Pages (from-to) | 794-797 |
Number of pages | 4 |
Journal | British Journal of Cancer |
Volume | 73 |
Issue number | 6 |
Publication status | Published - 1996 |
Keywords
- Advanced myeloma
- Cyclophosphamide
- Epirubicin
- Outpatient therapy
- Randomisation
ASJC Scopus subject areas
- Cancer Research
- Oncology